Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy
- 31 May 2004
- journal article
- Published by Elsevier in European Journal Of Cancer
- Vol. 40 (8) , 1170-1178
- https://doi.org/10.1016/j.ejca.2003.12.026
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Role of Body Surface Area in Dosing of Investigational Anticancer Agents in Adults, 1991-2001JNCI Journal of the National Cancer Institute, 2002
- Body Surface Area in Dosing Anticancer Agents: Scratch the Surface!JNCI Journal of the National Cancer Institute, 2002
- Dosing strategies for anticancer drugs: the good, the bad and body-surface areaEuropean Journal Of Cancer, 2002
- How to calculate the dose of chemotherapyBritish Journal of Cancer, 2002
- Body Surface Area as a Determinant of Pharmacokinetics and Drug DosingInvestigational New Drugs, 2001
- Body-surface area as a basis for dosing of anticancer agents: science, myth, or habit?Journal of Clinical Oncology, 1998
- Conventional Compared with Individualized Chemotherapy for Childhood Acute Lymphoblastic LeukemiaNew England Journal of Medicine, 1998
- Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative.Journal of Clinical Oncology, 1996
- Is Dose Normalization to Weight or Body Surface Area Useful in Adults?JNCI Journal of the National Cancer Institute, 1990
- Carboplatin dosage: prospective evaluation of a simple formula based on renal function.Journal of Clinical Oncology, 1989